[Skip to Content]
[Skip to Content Landing]
Views 1,167
Citations 0
Invited Commentary
May 29, 2019

Adjuvant Therapy for Ampullary Cancer

Author Affiliations
  • 1Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco
  • 2UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
  • 3Division of General Surgery, Section of Surgical Oncology and Hepatopancreaticobiliary Surgery, Department of Surgery, University of California, San Francisco
JAMA Surg. 2019;154(8):715. doi:10.1001/jamasurg.2019.1171

For periampullary cancers, including adenocarcinoma of the pancreas, ampulla, bile duct, and duodenum, a curative-intent pancreaticoduodenectomy provides the only chance for long-term survival. Adjuvant systemic therapy has been conclusively shown to improve survival after surgery for pancreatic cancer,1 but there is far less convincing evidence regarding the benefit of adjuvant therapy for other periampullary cancers.2 This lack of evidence is because of several factors: the low incidence of nonpancreas periampullary cancers, difficulty determining their exact site of origin, and, for biliary tract cancers, the pooling together of hilar, intrahepatic and extrahepatic cholangiocarcinomas, and gallbladder carcinomas under a single study “umbrella.”3,4 Complicating matters further is that such patients also frequently develop clinically relevant postoperative pancreatic fistulas, hampering their ability to receive timely adjuvant therapy.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words